Quality of Life Analysis of Arimidex Treatment in Postmenopausal Patients With Breast Cancer

Completed

• Conditions: Breast Cancer

• Registration Number: NCT00692289
• Lead Sponsor: AstraZeneca

Brief Summary

This is an open label, non-interventional quality of life analysis for Arimidex treated postmenopausal patients in early breast cancer by investigator's questionnaire

Detailed Description

Not available

Study Timeline

• Study Start: 2008-06
• Study First Submitted: 2008-06-05
• Study First Submitted QC: 2008-06-05
• Study First Posted: 2008-06-06
• Primary Completion: 2010-07
• Study Completion: 2010-07
• Status Verified: 2012-06
• Last Update Submitted: 2012-06-05
• Last Update Posted: 2012-06-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 1510

Inclusion Criteria

• Provision of informed consent
• Postmenopausal, hormon receptor positive patients with early breast cancer treated with Arimidex
• Investigators are requested to recruit patients only with at least 1 month prior Arimidex treatment.

Read More

Exclusion Criteria

• Allergy to substance of medication
• Pre-perimenopausal woman
• Woman not eligible for treatment

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Elements of the investigator questionnaire SF RAND-36 questionnaire	Quarterly (plus or minus 3 days )

Secondary Outcome Measures

Name	Time	Method
Investigator Assessment Report	Yearly (plus or minus 1 week )

Trial Locations

Locations (1)

Research Site; 🇭🇺 Zalaegerszeg, Hungary